Rational Project; The aim of this study is to increase the accessibility of the RAS test for metastatic colorectal cancer (mKRK) patients who are being treated in centers where CRAS and NRAS tests cannot be performed and aims to increase the test quality and reliability by providing scientific and technical support to these studies.

The use of monoclonal antibodies such as Panitumumab (Vectibix) in the treatment of metastatic colorectal cancer (mCCR) patients is currently one of the most effective treatment modalities, and is recommended only for patients with normal KRAS and NRAS DNA tests.

In project scope; In patients with metastatic colorectal cancer (MCRC), KRAS and NRAS mutations that direct therapy are examined in 2 stages. In the first stage, KRAS DNA test is applied and if the results are normal, NRAS DNA test is performed.

By KRAS DNA test, somatic KRAS mutations observed in 30-40% of colorectal cancers are examined and mutations observed in codon 12 & 13, 59, 61, 117 and 146 regions that cause drug resistance in patients are frequently detected.

NRAS DNA test is used in the first stage of the KRAS DNA test in cases found to be normal codon 12 & 13, 59, 61, 117 and 146 regions on the NRAS gene region are examined and mutations leading to drug resistance are detected in patients.

Please click here for more information.